Neuraxis (NRXS) Depreciation & Amortization (CF) (2022 - 2025)
Neuraxis (NRXS) posted Depreciation & Amortization (CF) of $24055.0 for Q4 2025, up 48.44% sequentially from $16205.0 in Q3 2025, and up 251.12% YoY from $6851.0 in Q4 2024.
Neuraxis (NRXS) Depreciation & Amortization (CF) (2022 - 2025) Analysis & Trends
Neuraxis has reported Depreciation & Amortization (CF) for 4 years, with the latest figure at $24055.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 251.12% year-over-year to $24055.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $53145.0 (up 58.88% YoY) and the FY2025 annual result came in at $59501.0, up 57.28% from the prior year.
- Depreciation & Amortization (CF) rose to $24055.0 in Q4 2025 per NRXS's latest filing, from $16205.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $24055.0 in Q4 2025 and troughed at $6356.0 in Q1 2025.
- A 4-year average of $11088.3 and a median of $10230.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 251.12% in 2025, down 40.8% in 2025.
- Over 4 years, Depreciation & Amortization (CF) stood at $12086.0 in 2022, then retreated by 13.66% to $10435.0 in 2023, then plunged by 34.35% to $6851.0 in 2024, then soared by 251.12% to $24055.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $24055.0, $16205.0, and $12885.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24,055.00 |
| Dec 31, 2025 | 24,055.00 |
| Sep 30, 2025 | 16,205.00 |
| Sep 30, 2025 | 16,205.00 |
| Jun 30, 2025 | 12,885.00 |
| Jun 30, 2025 | 12,885.00 |
| Mar 31, 2025 | 6,356.00 |
| Mar 31, 2025 | 6,356.00 |
| Dec 31, 2024 | 6,851.00 |
| Dec 31, 2024 | 6,851.00 |
| Sep 30, 2024 | 9,273.00 |
| Sep 30, 2024 | 9,273.00 |
| Jun 30, 2024 | 10,970.00 |
| Jun 30, 2024 | 10,970.00 |
| Mar 31, 2024 | 10,737.00 |
| Mar 31, 2024 | 10,737.00 |
| Dec 31, 2023 | 10,435.00 |
| Dec 31, 2023 | 10,435.00 |
| Sep 30, 2023 | 10,230.00 |
| Sep 30, 2023 | 10,230.00 |